Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

The development of targeted therapies for non-<i>BRAF</i> p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in <i>BRAF</i>, <i>NRAS</i>, or <i>NF1</i> form 10% of human melanomas and are heterogeneous in...

Full description

Bibliographic Details
Main Authors: Fanny Seraphine Krebs, Bianca Moura, Edoardo Missiaglia, Veronica Aedo-Lopez, Olivier Michielin, Petros Tsantoulis, Bettina Bisig, Mounir Trimech, Vincent Zoete, Krisztian Homicsko
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
cancer
<i>MAP2K1</i>
triple-negative melanoma
modelling
mutation
Online Access:https://www.mdpi.com/1422-0067/24/5/4520

Internet

https://www.mdpi.com/1422-0067/24/5/4520

Similar Items